98%
921
2 minutes
20
Purpose: We aimed to identify pathogenic variations in the UbiA prenyltransferase domain-containing protein 1 (UBIAD1) gene in a Japanese family with Schnyder corneal dystrophy (SCD).
Study Design: Clinical study METHODS: Three clinically diagnosed SCD patients from a single pedigree participated. Patients 1 and 2 were 69- and 65-year-old sisters, and patient 3 was the 42-year-old daughter of patient 1. Blood samples from the patients were obtained for genetic analysis. Mutation screening of the two UBIAD1 exons was performed using polymerase chain reaction (PCR)-based DNA sequencing.
Results: All participants were found to be heterozygous for the pathogenic missense variation c.695 A > G (p.Asn232Ser) in exon 2 of UBIAD1.
Conclusion: This is the first report on the pathogenic UBIAD1 variation c.695 A > G (p.Asn232Ser) in a Japanese population. SCD is a rare corneal dystrophy, and further research on additional cases will aid in the elucidation of disease mechanisms and development of therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10384-022-00951-y | DOI Listing |
Cornea
September 2025
Department of Ophthalmology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Purpose: To report early clinical outcomes of cultured human corneal endothelial cell (cHCEC) injection therapy (Vyznova) for bullous keratopathy (BK). To our knowledge, this is the first study reporting use of an initial commercial lot of Vyznova implemented at 3 independent institutions specializing in corneal transplantation in Japan.
Methods: This retrospective case series included 4 eyes of 4 patients (mean age, 76.
Cornea
September 2025
Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico.
Purpose: The aim of this study was to describe corneal biomechanical changes in individuals carrying the p.Ala546Asp mutation, compare those with and without visible corneal deposits, and explore their potential relevance for early biomechanical characterization.
Methods: A case series was conducted in a Mexican mestizo family with confirmed molecular diagnosis of granular corneal dystrophy type 2 (GCD2).
Ann Med Surg (Lond)
September 2025
Eye and Ear Hospital, Damascus, Syria.
Introduction And Importance: To report a successful treatment of lattice corneal dystrophy type 1 (LCD1) using topical cyclosporine (CsA) eye drop emulsion 0.05%.
Case Presentation: A 48-year-old female patient presented with bilateral LCD1characterized by corneal stromal lattice lines and visual symptoms.
Invest Ophthalmol Vis Sci
September 2025
Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China.
Purpose: To develop and characterize a novel mouse model of granular corneal dystrophy type II (GCD2) using CRISPR/Cas9 technology and explore the underlying pathogenesis of transforming growth factor-beta-induced protein (TGFBIp) aggregation.
Methods: CRISPR/Cas9 technology was employed to introduce the R124H mutation in the TGFBI gene of mice. Genomic sequencing and polymerase chain reaction confirmed the mutation.
Cureus
July 2025
Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, GRC.
Fungal keratitis is a rare but severe complication following penetrating keratoplasty (PKP). We report the clinical course, rapid deterioration, and management of a case of keratitis occurring three months after PKP. A 69-year-old woman with Fuchs' endothelial dystrophy developed pseudophakic bullous keratopathy following cataract surgery.
View Article and Find Full Text PDF